Wavelength-Pharmaceuticals-Insert
X

Find Neurology Drugs in Phase II Clinical Development in CANADA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABT-346

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bloom Burton Securities

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 09, 2020

            Details:

            The net proceeds of the Offering will be used to fund activities required for large market partnering and in support of the Phase 3 program for ATB-346, for business development activities, and for advancing the other drugs in the Company’s pipeline including ATB-352.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lysergide

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Liechti Lab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 08, 2020

            Details:

            Mind Medicine is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel’s Liechti Lab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABT-346

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            Conference will focus on the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session for analysts.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABT-346

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            The 150 mg dose of ATB-346, although not powered for statistical significance, demonstrated more potency than expected and the lowest effective dose is still to be established.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABT-346

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            Antibe's partner, Veristat, was able to complete the Phase 2B dose-ranging, efficacy study for ATB-346 and capture all patient data without compromising the size and integrity of the study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Cannabidiol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            The receipt of the DEA Schedule 1 license is a significant milestone in the advancement of the Plenitude trial and ultimately getting QIXLEEF™ into the market.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABT-346

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 28, 2020

            Details:

            The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis (OA) pain compared to placebo in 360 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Cannabidiol

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            The FDA validated Tetra’s nonclinical program proposed to support clinical trials in non-cancer pain indications and the New Drug Application.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Montelukast Sodium

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2020

            Details:

            Health Canada has issued a No Objection Letter in response to IntelGenx’s amended Clinical Trial Application for the ongoing Montelukast VersaFilm® Phase 2a clinical trial for Alzheimer’s Disease.